Cognition Therapeutics, Inc. (CGTX)
Nasdaq: CGTX · Biological Products, (No Diagnostic Substances) · Purchase, NY · filing with the SEC since 2009
Who owns Cognition Therapeutics, Inc.
As filed with the SECHolders of 5% or more
1
Aaron G.L. Fletcher holds 6.9% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed Sep 23, 2025 says.
Directors and officers
17
report now, of 32 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Aaron G.L. Fletcher
SCHEDULE 13D/A · filed Sep 23, 2025 · Common Stock, par value $0.001 per share
Pathstone Family Office, LLC
SCHEDULE 13G · filed Feb 4, 2025 · Common stock · reported falling below 5%
What CGTX reports owning in othersstakes of 5% or more, and other ties
Cognition Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
3purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window3 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Ricciardi Lisa | CEO & President | 0 | $0 | 0 | 1 | $0 |
| Doyle John Brendan | Chief Financial Officer | 0 | $0 | 0 | 1 | $0 |
| Caggiano Anthony | Chief Medical Officer | 0 | $0 | 0 | 1 | $0 |